ClinicalTrials.gov
public full text
Public Domain
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
This is a phase I, single-blind, randomized, placebo-controlled, single-center study in healthy subjects using a staggered approach to dosing. 30 subjects will be randomized to receive 10 μg Flexyn2a candidate vaccine with or without adjuvant or placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)#1170719
- Estimating the impact of Shigella vaccines on growth outcomes and implications for clinical trial design#151576
- Estimating the impact of <i>Shigella</i> vaccines on growth outcomes and implications for clinical trial design#154111
- Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old#628565
- Phase 2 Shigella Vaccine and Challenge#321563
Record · ID 876033
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive